| Budget Amount *help |
¥49,790,000 (Direct Cost: ¥38,300,000、Indirect Cost: ¥11,490,000)
Fiscal Year 2010: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2009: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2008: ¥32,890,000 (Direct Cost: ¥25,300,000、Indirect Cost: ¥7,590,000)
|
|---|
| Research Abstract |
The purpose of this study is to concentrate the stem (tumor-initiating) cell fraction of sarcoma, and then to develop stem cell-targeted agent, utilizing cell-targeting technologies with oncolytic virus. Several lines of highly tumorigenic osateosarcoma were isolated. Tumor-initiating cells from gastrointestinal stromal tumor, sarcoma-like tumor, were concentrated into the cellular fraction characterized with the cell surface marker CD133(Low/-) in vitro. Those cells were shown to be silenced in the hypoxic region of tumor, and resistant to Imatinib treatment. Tumor-initiating cells from sarcomatous mesothelioma were concentrated into the cellular fraction with CD133 (Low/-) and CD44(+). We showed that our HSV-1 oncolytic virus d12ODDΔRR targeting hypoxic microenvironment of tumor successfully destroyed tumor-initiating cells from stromal tumor and mesothelioma.
|
